Evidence map›Paper›PMID 36976786›Full record

ArticleHead & neck2023

Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs.

William J Benjamin, Pratyusha Yalamanchi, Jeremy M G Taylor, Nicholas Lenze, Francis P Worden, Steven B Chinn, Michelle M Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William J BenjaminUniversity of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0003-4116-7408
Pratyusha YalamanchiDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jeremy M G TaylorDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Nicholas LenzeDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0002-2126-6663
Francis P WordenDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Steven B ChinnDepartment of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Michelle M ChenDepartment of Otolaryngology - Head and Neck Surgery, Stanford University, Stanford, California, USA.ORCID 0000-0002-6988-5658

Funding

Integrated Analysis of Germline and Somatic Mutations in Young, Low-Risk and Older, High-Risk Oral Cavity CancerK08CA226350 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINN, STEVEN BENNETT · 2018 to 2021
$882k
NCI NIH HHS K08 CA226350
6 · The paper itself

Abstract

backgroundThe impact of monoclonal antibody therapy (mAB) for advanced head and neck cancer on end-of-life health care utilization and costs has yet to be adequately studied.

methodsRetrospective cohort study of patients aged 65 and over with a diagnosis of head and neck cancer between 2007 and 2017 within the SEER-Medicare registry assessing the impact of mAB therapy (i.e., cetuximab, nivolumab, or pembrolizumab) on end-of-life health care utilization (ED visits, inpatient admissions, ICU admissions, and hospice claims) and costs.

resultsOf 12 544 patients with HNC, 270 (2.2%) utilized mAB therapy at the end-of-life period. On multivariable analyses adjusting for demographic and clinicopathologic characteristics, there was a significant association between mAB therapy and emergency department visits (OR: 1.38, 95% CI: 1.1-1.8, p = 0.01) and healthcare costs (β: $9760, 95% CI: 5062-14 458, p < 0.01).

conclusionsmAB use is associated with higher emergency department utilization and health care costs potentially due to infusion-related and drug toxicity expenses.

Indexed as

Head and Neck NeoplasmsTerminal CareAgedDeathHealth Care CostsHumansMedicareNivolumabRetrospective StudiesUnited StatesNivolumabend-of-life carehead and neck cancerhealth care costshealth care utilization

Identifiers

PMID36976786
PMCPMC10314811

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.